Senior Vice President, Global Innovation Policy Center (GIPC), U.S. Chamber of Commerce Not long ago, patients with severe obesity faced a stark choice: major surgery or a lifetime of managing a condition that medicine had largely given up on. Today, that has changed. A new generation of anti-obesity medicines—including GLP-1 therapies—are delivering meaningful, lasting weight loss while reducing the risk of heart disease, diabetes, and other life-threatening complications.